CDP-Choline

Cytidine 5'-diphosphocholine (CDP-choline, citicoline) is an endogenous mononucleotide composed of cytidine and choline linked by a diphosphate bridge, functioning as the direct and obligate precursor to phosphatidylcholine in the Kennedy pathway of membrane phospholipid biosynthesis first characterized by Eugene P. Kennedy and Samuel B. Weiss in 1956. Exogenous administration of CDP-choline supplies the central nervous system with both choline (the substrate for acetylcholine synthesis and for phosphatidylcholine assembly) and cytidine (which is converted in human plasma to uridine, a pyrimidine nucleoside involved in synaptic glycoprotein synthesis and in the potentiation of nerve growth factor signaling). Oral bioavailability exceeds 90 percent in humans, and the compound is rapidly hydrolyzed in the intestinal wall and liver to its two circulating components, cytidine and choline, which cross the blood-brain barrier independently and are reassembled intracellularly by CTP:phosphocholine cytidylyltransferase, the rate-limiting enzyme of the Kennedy pathway. The pharmacological profile encompasses membrane phospholipid restoration, acetylcholine augmentation, dopaminergic modulation, attenuation of phospholipase A2-mediated arachidonic acid release, and preservation of cardiolipin and sphingomyelin content in ischemic neural tissue. These mechanisms collectively support the neuroprotective activity demonstrated in rodent models of focal and global cerebral ischemia, traumatic brain injury, and excitotoxic neuronal death.

The clinical evidence base for CDP-choline spans more than 11,000 patients across multiple indications. In acute ischemic stroke, the compound was studied in the International Citicoline Trial on Acute Stroke (ICTUS), a 2,298-patient randomized, double-blind, placebo-controlled trial that produced a neutral primary endpoint (global recovery odds ratio 1.03, 95 percent confidence interval 0.86 to 1.25) but demonstrated benefit in prespecified subgroups including patients older than 70 years and those with less severe baseline deficits. An independent meta-analysis of ten randomized controlled trials subsequently reported a pooled odds ratio of 1.56 (95 percent confidence interval 1.12 to 2.16) favoring independence with citicoline treatment. In traumatic brain injury, the Citicoline Brain Injury Treatment Trial (COBRIT), a 1,213-patient Phase 3 trial published by Zafonte et al. in JAMA (2012), did not demonstrate benefit on functional or cognitive status at 90 days. In age-related cognitive impairment, a 2021 randomized controlled trial demonstrated significant improvement in episodic memory in healthy older adults after 12 weeks of oral supplementation at 500 mg daily. In chronic cerebrovascular disease, Cochrane meta-analysis identified positive short-term effects on memory and behavior, though evidence was limited by study duration and heterogeneity. The compound is registered as a pharmaceutical agent in over 60 countries for neurological indications (marketed as Somazina, Recognan, Ceraxon, and numerous generics) and is classified as a dietary supplement in the United States, where it has received Generally Recognized as Safe (GRAS) status. The toxicological profile is favorable: the oral LD50 in rats exceeds 2,000 mg/kg, no serious adverse events have been attributed to the compound in controlled trials, and adverse event rates in meta-analyses are comparable to placebo. This monograph reviews the chemistry, biosynthetic role, and stereochemistry of CDP-choline; the multitarget neuroprotective and cholinergic pharmacology; the complete pharmacokinetic record including the cytidine-to-uridine conversion unique to primates; the clinical evidence base across stroke, traumatic brain injury, cognitive impairment, glaucoma, and substance dependence indications; sourcing, reconstitution, and quality verification; stack interactions; adverse events and safety; and a comparative assessment of five alternative choline-pathway or membrane-trophic agents against CDP-choline on five competency standards.